Temozolomide: The evidence for its therapeutic efficacy in malignant astrocytomas

Omar, Ayman I.; Mason, Warren P.
January 2009
Core Evidence;2009, Vol. 4 Issue 1, p93
Academic Journal
Introduction: Malignant gliomas are a heterogeneous group of primary central nervous system neoplasms that represent less than 2% of all cancers yet carry a significant burden to society. They are frequently associated with considerable and progressive neurological disability and are ultimately intractable to all forms of treatment. Temozolomide (TMZ) is a new second generation DNA alkylating agent that has become part of malignant astrocytoma management paradigms because of its proven efficacy, ease of administration, and favorable toxicity profile. Aims: To review the role of TMZ in the management of malignant astrocytomas (World Health Organization grades III and IV) including newly diagnosed (n) and recurrent (r) anaplastic astrocytomas (AA) and glioblastomas. Evidence review: A series of pivotal clinical trials have established a role for TMZ in the treatment of malignant astrocytomas. A large phase II trial examining the role of TMZ in rAA showed a response rate of 35%, and a 6-month progression-free survival of 46%. This led to the accelerated approval of TMZ by the FDA and the EU for the treatment of rAA. Evidence for a role of TMZ in nAA is currently limited but research is ongoing in this area. The role of TMZ in the management of glioblastoma at the time of recurrence (rGBM) is less impressive but evidence for its activity was demonstrated in two large phase II trials that led to the approval of TMZ for this indication in Europe and Canada but not in the US. A recent large prospective randomized phase III trial showed that the addition of TMZ during and after radiation therapy (RT) in newly diagnosed (nGBM) patients prolonged median overall survival by 2.5 months; perhaps more importantly, the 2-year survival rate for patients receiving TMZ and RT was 26% compared with 10% for those receiving RT alone. Concurrent TMZ with RT followed by adjuvant TMZ has become the standard of care for nGBM patients. Based on the evidence presented in this trial, TMZ received approval from the FDA and the EU for patients with nGBM in 2005. Place in therapy: There is evidence to support the use of TMZ for the following diseases in the order of most to least convincing: nGBM, rAA, rGBM, and nAA. This order may quickly change as more trials are being designed and implemented, particularly with novel TMZ dosing schedules.


Related Articles

  • Trabectedin: the evidence for its place in therapy in the treatment of soft tissue sarcoma. Thornton, Katherine A. // Core Evidence;2009, Vol. 4 Issue 1, p191 

    Introduction: Soft tissue sarcoma accounts for less than 1% of all malignant neoplasms and is comprised of a very heterogeneous group of tumors with over 50 different subtypes. Due to its diversity and rarity, developing new therapeutics has been difficult, at best. The standard of care in the...

  • Lasofoxifene: Evidence of its therapeutic value in osteoporosis. Gennari, Luigi; Merlotti, Daniela; De Paola, Vincenzo; Nuti, Ranuccio // Core Evidence;2009, Vol. 4 Issue 1, p113 

    Introduction: Osteoporosis is a skeletal disorder characterized by compromised bone strength and increased risk of fracture. It is a common disorder in elderly subjects and represents a major public health problem, affecting up to 40% postmenopausal women and 15% of men. Among the several...

  • Possible molecular targets for therapeutic applications of caffeic acid phenethyl ester in inflammation and cancer. Murtaza, Ghulam; Sajjad, Ashif; Mehmood, Zahid; Shah, Syed H.; Siddiqi, Abdul R. // Journal of Food & Drug Analysis;Mar2015, Vol. 23 Issue 1, p11 

    Of the various derivatives of caffeic acid, caffeic acid phenethyl ester (CAPE) is a hydrophobic, bioactive polyphenolic ester obtained from propolis extract. The objective in writing this review article was to summarize all published studies on therapeutics of CAPE in inflammation and cancer to...

  • Application of the ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale to Assess the Value of Abiraterone and Enzalutamide in Advanced Prostate Cancer. Wong, Sarah E.; Everest, Louis; Jiang, Di M.; Saluja, Ronak; Chan, Kelvin K.W.; Sridhar, Srikala S. // Journal of Oncology Practice;2020 Supplement1, Vol. 16, pe201 

    PURPOSE: As novel hormonal therapies, such as abiraterone and enzalutamide, move into earlier stages of treatment of advanced prostate cancer, there are significant cost implications. We used the ASCO Value Framework (AVF) and European Society of Medical Oncology (ESMO) Magnitude of Clinical...

  • Desvenlafaxine in major depressive disorder: an evidence-based review of its place in therapy. Lieberman, Daniel Z.; Massey, Suena H. // Core Evidence;2009, Vol. 4 Issue 1, p67 

    Introduction: Desvenlafaxine, the active metabolite of venlafaxine, is a serotonin norepinephrine reuptake inhibitor (SNRI) recently approved for the treatment of major depressive disorder. It is one of only three medications in this class available in the United States. Aims: The objective of...

  • Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation. Deibert, Peter; Xander, Carola; Blum, Hubert E.; Becker, Gerhild // Core Evidence;2009, Vol. 4 Issue 1, p247 

    Introduction: Constipation is a distressing side effect of opioid treatment, being so irksome in some cases that patients would rather suffer the pain than the side effect of opioid analgesics. Stool softeners or stimulating laxatives are often ineffective or even aggravate the situation. A new...

  • Luliconazole for the treatment of fungal infections: an evidence-based review. Khanna, Deepshikha; Bharti, Subhash // Core Evidence;2014, Vol. 9, p113 

    Abstract: Luliconazole is an imidazole antifungal agent with a unique structure, as the imidazole moiety is incorporated into the ketene dithioacetate structure. Luliconazole is the R-enantiomer, and has more potent antifungal activity than lanoconazole, which is a racemic mixture. In this...

  • Ustekinumab: an evidence-based review of its effectiveness in the treatment of psoriasis. Krulig, Eliana; Gordon, Kenneth B. // Core Evidence;2010, Vol. 5 Issue 1, p11 

    Introduction: Psoriasis is a chronic inflammatory skin disease affecting approximately 2% to 3% of the population worldwide. Discoveries over the past 3 to 5 years have significantly altered our view of psoriasis as primarily a T-cell mediated condition. The most recent research has demonstrated...

  • Exforge® (amlodipine/valsartan combination) in hypertension: the evidence of its therapeutic impact. Krzesinski, Jean-Marie; Cohen, Eric P. // Core Evidence;2009, Vol. 4 Issue 1, p1 

    Introduction: Hypertension is an important risk factor for cardiovascular disease and its management requires improvement. New treatment strategies are needed. Aims: This review analyses one of these strategies, which is the development of effective and safe combination therapy. Indeed, at least...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics